Arcturus Therapeutics (ARCT) had a challenging fourth quarter, with revenue and earnings falling short of analyst expectations. Their annual revenue took a dip, dropping $14.5 million from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback